Tissue-specific roles of FXR in CVD and NASH
FXR 在 CVD 和 NASH 中的组织特异性作用
基本信息
- 批准号:10683976
- 负责人:
- 金额:$ 42.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-21 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAgonistApolipoproteinsArterial Fatty StreakAtherosclerosisAutomobile DrivingBile AcidsBiliaryBiologicalBiological MarkersBlood VesselsCardiovascular DiseasesCardiovascular systemCarotid Artery Ulcerating PlaqueCellsCholesterolCholesterol HomeostasisClinicalCollaborationsCoronary ArteriosclerosisDepositionDevelopmentDietary ComponentDiseaseDisease modelEpitopesExcretory functionExtrahepaticFGF19 geneFibroblast Growth FactorFibrosisFoam CellsFunctional disorderGeneticGenetic TranscriptionGoalsHepaticHepatitisHigh Density LipoproteinsHyperlipidemiaIn VitroInflammationInsulin ResistanceIntestinesLesionLipidsLipoproteinsLiverLiver diseasesLysophosphatidylcholinesMacrophageMediatingMetabolismModelingMusPathway interactionsPatientsPeptidesPhysiologyPredictive ValueReceptor ActivationReceptor Cross-TalkRegulationReportingRiskRoleSamplingSerumSignal TransductionSteatohepatitisTissuesTriglyceridesatherogenesisatheroprotectivebiobankblood glucose regulationcardiovascular disorder riskcomparativedisorder riskfatty liver diseasegain of functionhuman diseasehypercholesterolemiaindexinginsightliver injuryloss of functionmouse modelnonalcoholic steatohepatitisoxidationpatient populationpharmacologicpre-clinicalprogramsprotective effectreceptorreceptor expressionrepairedrepositoryreverse cholesterol transportsterol homeostasistargeted treatment
项目摘要
PROJECT SUMMARY
Project 2. Tissue-specific roles of FXR in CVD and NASH
Hyperlipidemia and insulin resistance are commonly associated with both cardiovascular and liver diseases,
however causal relationships between atherosclerosis and NASH are not well established. The farnesoid X
receptor (FXR) is a regulator of systemic sterol and glucose homeostasis, and is known to contribute to the
initiation and progression of both cardiovascular and liver diseases. Loss of hepatic FXR, but not intestinal
FXR, results in elevated circulating and hepatic cholesterol and triglyceride levels. In contrast, both hepatic and
intestinal FXR enhance hepatic repair and cholesterol excretory activities. Consistent with this, FXR agonists
reliably reduce atherosclerosis and have been reported to show promising effects in liver disease models.
Thus, the goal of Project 2 is to dissect the tissue-specific activities of FXR in the context of integrative
hepatovascular pathophysiology. Specifically, we will explore the notion that FXR drives distinct protective
programs in cardiovascular and liver diseases.
The macrophage is central in the development of atherosclerosis and steatotic hepatitis through the deposition
of vascular fatty lesions, as well as driving or resolving liver damage. As a key regulator of inflammation and
multiple steps in the reverse cholesterol transport and excretion pathways, FXR is an established target for
mitigating the development of foam cells that underlie vascular plaque deposition. Our preliminary findings
indicate that plaque deposition and facets of liver disease are divisible with tissue-specific modulation of FXR
activities.
This project will explore the hypothesis that tissue-specific modulation of FXR will affect the progression of
CVD and NASH. To achieve this goal, proprietary FXR agonists that target either the liver (hepFexD) or gut
(intFexD) will be used in combination with ldlr-/- mice lacking FXR expression in either the liver (hepFXRko) or
the intestine (intFXRko) to dissect the association of fatty liver disease and CVD risk. In Aim 1, the impact of
hepatic FXR on atherosclerosis and liver disease will be explored, including the contribution from FXR-
regulated crosstalk between parenchymal and non-parenchymal cells in collaboration with Project 1, and the
role for hepatic FXR in OSE levels or clearance in collaboration with Project 3. In Aim 2, the ability of systemic
signaling from intestinal FXR to affect macrophage cholesterol homeostasis will be determined in collaboration
with Project 1. Finally, the relevance of our pre-clinical findings studies to human disease will be determine by
interrogating curated clinical samples for biomarkers of FXR activity in collaboration with Project 4. The
proposed comprehensive genetic, pharmacologic and comparative biological approach will provide a better
understanding of the physiology and mechanisms by which tissue-specific FXR crosstalk impacts
atherosclerosis and steatohepatitis.
项目摘要
项目2. FXR在CVD和NASH中的组织特异性作用
高血压和胰岛素抵抗通常与心血管和肝脏疾病有关,
然而,动脉粥样硬化和NASH之间的因果关系还没有很好地建立。法尼醇X
受体(FXR)是全身固醇和葡萄糖稳态的调节剂,已知有助于
心血管和肝脏疾病的发生和发展。肝脏FXR丧失,但肠道FXR未丧失
FXR导致循环和肝脏胆固醇和甘油三酯水平升高。相比之下,肝脏和
肠FXR增强肝修复和胆固醇排泄活性。与此一致,FXR激动剂
可靠地减少动脉粥样硬化,并已报道在肝脏疾病模型中显示出有希望的效果。
因此,项目2的目标是在整合的背景下剖析FXR的组织特异性活动。
肝血管病理生理学具体来说,我们将探讨FXR驱动不同保护性
心血管和肝脏疾病的治疗方案。
巨噬细胞是通过沉积在动脉粥样硬化和脂肪性肝炎的发展中心
血管脂肪病变,以及驱动或解决肝损伤。作为炎症的关键调节因子,
在胆固醇逆向转运和排泄途径中,FXR是一个既定的靶点,
减轻了血管斑块沉积基础的泡沫细胞的形成。我们的初步研究结果
表明斑块沉积和肝脏疾病方面可通过FXR的组织特异性调节来划分
活动
本项目将探讨FXR的组织特异性调节将影响肿瘤进展的假设。
CVD和NASH。为了实现这一目标,靶向肝脏(hepFexD)或肠道的专有FXR激动剂
(intFexD)将与在肝脏(hepFXRko)中缺乏FXR表达的ldlr-/-小鼠组合使用,或与在肝脏(hepFXRko)中缺乏FXR表达的ldlr-/-小鼠组合使用。
肠道(intFXRko)来剖析脂肪肝疾病和CVD风险的关联。在目标1中,
将探讨肝FXR对动脉粥样硬化和肝病的作用,包括FXR-
与项目1合作,调节实质和非实质细胞之间的串扰,
肝脏FXR在OSE水平或清除中的作用,与项目3合作。在目标2中,系统的能力
来自肠道FXR的信号传导影响巨噬细胞胆固醇稳态将在合作中确定
项目1。最后,我们的临床前研究结果与人类疾病的相关性将通过以下方式确定:
与项目4合作,询问策划的临床样本中FXR活性的生物标志物。的
综合遗传学、药理学和比较生物学的方法将提供一个更好的
了解组织特异性FXR串扰影响的生理学和机制
动脉粥样硬化和脂肪性肝炎。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RONALD M EVANS其他文献
RONALD M EVANS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RONALD M EVANS', 18)}}的其他基金
Project 1: Overcoming therapeutic resistance in pancreatic cancer through epigenetic reprogramming
项目1:通过表观遗传重编程克服胰腺癌的治疗耐药性
- 批准号:
10629063 - 财政年份:2023
- 资助金额:
$ 42.89万 - 项目类别:
Tissue-specific roles of FXR in CVD and NASH
FXR 在 CVD 和 NASH 中的组织特异性作用
- 批准号:
10461065 - 财政年份:2020
- 资助金额:
$ 42.89万 - 项目类别:
Tissue-specific roles of FXR in CVD and NASH
FXR 在 CVD 和 NASH 中的组织特异性作用
- 批准号:
10262919 - 财政年份:2020
- 资助金额:
$ 42.89万 - 项目类别:
Engineering human islet-like organoids for transplantation
工程化人类胰岛样器官用于移植
- 批准号:
10161781 - 财政年份:2018
- 资助金额:
$ 42.89万 - 项目类别:
Engineering human islet-like organoids for transplantation
工程化人类胰岛样器官用于移植
- 批准号:
9788431 - 财政年份:2018
- 资助金额:
$ 42.89万 - 项目类别:
BD2K: INTEROPERABILITY OF NURSA WITH PHARMGKB AND DKNET
BD2K:NURSA 与 PARMGKB 和 DKNET 的互操作性
- 批准号:
9057203 - 财政年份:2012
- 资助金额:
$ 42.89万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 42.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 42.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 42.89万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 42.89万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 42.89万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 42.89万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 42.89万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 42.89万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 42.89万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 42.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)